XML 68 R54.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Data - Revenues by Geographic Areas (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2023
Segment Reporting Information [Line Items] |  |  |
Revenues | $ 21,840 | $ 20,178 | $ 19,372
Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 21,840 | 20,245 | 19,372
Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 11,456 | 10,074 | 9,502
Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 5,167 | 5,191 | 5,133
Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 5,217 | 4,980 | 4,736
Corporate and All Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 0 | (67) | 0
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 12,790 | 11,663 | 11,113
United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 6,916 | 5,964 | 5,488
United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,328 | 2,310 | 2,377
United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 3,545 | 3,394 | 3,247
United States | Corporate and All Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 0 | (6) | 0
International |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 9,049 | 8,515 | 8,258
International | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,540 | 4,110 | 4,014
International | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,838 | 2,881 | 2,756
International | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,671 | 1,586 | 1,489
International | Corporate and All Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 0 | (62) | 0
Medication Delivery Solutions | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 4,575 | 4,429 | 4,293
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,789 | 2,661 | 2,519
Medication Delivery Solutions | International | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,787 | 1,768 | 1,774
Medication Management Solutions | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 3,474 | 3,297 | 2,980
Medication Management Solutions | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,810 | 2,627 | 2,303
Medication Management Solutions | International | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 664 | 670 | 677
Pharmaceutical Systems | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 2,324 | 2,273 | 2,229
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 659 | 629 | 666
Pharmaceutical Systems | International | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,666 | 1,644 | 1,563
Advanced Patient Monitoring | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,082 | 74 | 0
Advanced Patient Monitoring | United States | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 658 | 47 | 0
Advanced Patient Monitoring | International | Operating Segments | Medical |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 424 | 27 | 0
Specimen Management | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,871 | 1,833 | 1,737
Specimen Management | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 981 | 952 | 906
Specimen Management | International | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 890 | 882 | 831
Diagnostic Solutions | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,838 | 1,846 | 1,888
Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 755 | 782 | 869
Diagnostic Solutions | International | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,083 | 1,064 | 1,019
Biosciences | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,458 | 1,512 | 1,509
Biosciences | United States | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 593 | 577 | 603
Biosciences | International | Operating Segments | Life Sciences |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 865 | 935 | 906
Surgery | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,572 | 1,492 | 1,497
Surgery | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,175 | 1,130 | 1,159
Surgery | International | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 397 | 363 | 338
Peripheral Intervention | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,996 | 1,933 | 1,865
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,067 | 1,029 | 1,016
Peripheral Intervention | International | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 929 | 904 | 849
Urology and Critical Care | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,649 | 1,554 | 1,374
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | 1,303 | 1,236 | 1,073
Urology and Critical Care | International | Operating Segments | Interventional |  |  |
Segment Reporting Information [Line Items] |  |  |
Revenues | $ 345 | $ 319 | $ 301

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_AdvancedPatientMonitoringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SpecimenManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_DiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |